Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Related Questions
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
What are your treatment options and preferences for classical EGFR mutated NSCLC upon widespread progression following first line chemo/osimertinib?
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
Is there a biomarker for which patients benefit from tarlatamab?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
